Management of Presyncope and Sinus Bradycardia in Post-Ablation Patients

Assessment and Immediate Management

The American College of Cardiology suggests that discontinuing bisoprolol immediately and considering reducing or discontinuing flecainide is necessary, as both medications can cause significant bradycardia, especially when used in combination, in patients with presyncope and sinus bradycardia 1, 2
Beta-blockers like bisoprolol can exacerbate bradycardia when combined with other antiarrhythmic medications, such as flecainide, in patients with presyncope, which suggests hemodynamic compromise 3
The combination of bisoprolol and flecainide is particularly concerning in a patient with presyncope, which suggests hemodynamic compromise, and requires close monitoring of vital signs and cardiac rhythm 2

The American College of Cardiology recommends discontinuing bisoprolol immediately and considering reducing or temporarily discontinuing flecainide if bradycardia persists, and monitoring vital signs and cardiac rhythm closely in patients with presyncope and sinus bradycardia 2, 5
Serial ECGs should be obtained to assess for improvement in heart rate, and ambulatory monitoring should be considered to evaluate for other arrhythmias or pauses in patients with presyncope and sinus bradycardia 1, 2

The American College of Cardiology suggests that for patients with atrial fibrillation post-ablation who require rhythm control, flecainide alone may be sufficient without concurrent beta-blocker therapy, and if rate control is still needed, a lower dose of a different beta-blocker or a non-dihydropyridine calcium channel blocker should be considered 7, 4
Amiodarone may be considered as an alternative if the patient cannot tolerate flecainide or continues to have bradycardia, according to the American College of Cardiology 6, 4

The American College of Cardiology recommends avoiding restarting beta-blocker therapy until bradycardia has completely resolved and the patient has been stable on a reduced dose or alternative antiarrhythmic regimen, and being aware that flecainide can increase pacing thresholds if the patient eventually requires a pacemaker 2
Out-of-hospital drug termination with flecainide should be avoided in patients with symptomatic sick sinus syndrome or AV conduction disturbances, and transtelephonic monitoring or other ECG surveillance methods should be used when adjusting antiarrhythmic therapy, according to the American College of Cardiology 1

The American College of Cardiology suggests that if the patient continues to have symptomatic bradycardia despite medication adjustments, electrophysiology consultation for possible pacemaker implantation should be considered, and for patients who had AF ablation, antiarrhythmic drugs are often only needed temporarily (3-6 months) post-procedure 2, 5
Regular ECG monitoring should be performed during follow-up to assess heart rate and conduction intervals, according to the American College of Cardiology 5